Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10313MR)

This product GTTS-WQ10313MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10313MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15243MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ122MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ3593MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ6299MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ3339MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ2758MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ13692MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ7451MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GBR-830
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW